Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast Cancer
Globe Newswire•13/10/2026•07:01 ET
0
Key Highlights
- ➤Prelude (PRLD) signs Lilly collaboration and supply agreement for PRT13722 combinations
- ➤Phase 1 trial enrollment expected in fourth quarter of 2026
- ➤Abemaciclib and imlunestrant combinations will be evaluated in HR+/HER2- breast cancer
- ➤FDA cleared Prelude to proceed with PRT13722 Phase 1 study under its IND
- ➤PRT13722 showed preclinical synergy with endocrine therapies and CDK4/6 inhibitors
Expert Statements
Sean Brusky, Chief Business & Strategy Officer of Prelude
“This collaboration with Lilly enables us to evaluate the potential of PRT13722 in combinations with abemaciclib and imlunestrant in patients with HR+ breast cancer.”
Sean Brusky, Chief Business & Strategy Officer of Prelude
“We are taking a highly differentiated approach to this clinically validated target.”
Sean Brusky, Chief Business & Strategy Officer of Prelude
“Our preclinical data demonstrate that selectively degrading KAT6A has the potential to improve upon the efficacy and hematologic toxicity seen with dual KAT6A/B inhibitors, thereby enabling combination approaches that could advance the standard of care in earlier lines of therapy.”
Sean Brusky, Chief Business & Strategy Officer of Prelude
“We are pleased to be partnering with Lilly, recognized global leaders in breast cancer, to generate these important data for patients.”
Combination cohorts are part of Prelude’s Phase 1 trial evaluating PRT13722 in patients with HR+/HER2- breast cancer, on track to initiate enrollment in the fourth quarter of 2026
The collaboration is underpinned by pre-clinical data that demonstrate monotherapy efficacy for PRT13722 and synergy with both CDK4/6 inhibitors and endocrine therapies across multiple HR+ breast cancer models
Get started
Create a free account to read the full story.